Alterity Therapeutics Limited - Asset Resilience Ratio
Alterity Therapeutics Limited (PBN) has an Asset Resilience Ratio of 16.30% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Alterity Therapeutics Limited to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Alterity Therapeutics Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PBN total asset value.
Liquid Assets Composition Over Time
This chart breaks down Alterity Therapeutics Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Alterity Therapeutics Limited's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €7.50 Million | 16.3% |
| Total Liquid Assets | €7.50 Million | 16.30% |
Asset Resilience Insights
- Good Liquidity Position: Alterity Therapeutics Limited maintains a healthy 16.30% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Alterity Therapeutics Limited Industry Peers by Asset Resilience Ratio
Compare Alterity Therapeutics Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Alterity Therapeutics Limited (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Alterity Therapeutics Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 16.30% | €7.50 Million ≈ $8.77 Million |
€46.03 Million ≈ $53.81 Million |
-- |
| 2024-06-30 | 0.00% | €0.00 ≈ $0.00 |
€19.22 Million ≈ $22.47 Million |
-- |
| 2018-06-30 | 0.05% | €9.51K ≈ $11.12K |
€18.73 Million ≈ $21.89 Million |
-0.12pp |
| 2017-06-30 | 0.17% | €43.99K ≈ $51.43K |
€25.28 Million ≈ $29.56 Million |
-- |
| 2016-06-30 | 0.00% | €0.00 ≈ $0.00 |
€33.73 Million ≈ $39.43 Million |
-- |
About Alterity Therapeutics Limited
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more